Nexsen

12/02/2025

🌍 Tackling a global crisis, one test at a time.

NEXSEN is taking a bold step forward in the fight against Group B Strep (GBS), a leading cause of neonatal deaths worldwide. Their research into the creation of an innovative rapid test for early diagnosis could revolutionise maternal and neonatal care. As they gear up for their IPO, this breakthrough has never been more important.

🔗 Check out how NEXSEN is changing the game: [Read more]

https://stockhead.com.au/health/biocurious-ipo-candidate-nexsen-biotech-tackles-global-infant-killer-with-early-diagnosis-tool/

Slated to list on the ASX next year, Nexsen Biotech has developed a simple device to diagnose the infant killer group B streptococcus.

24/12/2024

"🎄✨ From all of us at Nexsen Biotech, we wish you a Merry Christmas and a Happy New Year! May your holidays be filled with joy, peace, and good health. Here's to a brighter, healthier future together! 🌟🎁

06/12/2024

🌟 Biotechnology: Shaping Healthier Beginnings 👶🔬

Biotechnology is transforming maternal and newborn healthcare, offering innovative solutions that save lives and ensure safer journeys into parenthood.

From rapid diagnostics that could detect infections like Group B Strep early, to advanced prenatal testing and cutting-edge treatments, biotech is empowering healthcare providers to better protect mothers and their babies.

💡 The Impact:
✨ Early infection detection for healthier pregnancies.
✨ Personalized care for mothers and newborns.
✨ Groundbreaking research driving life-saving innovations.

Together, science and compassion are creating a brighter, healthier future for every family. 💖

Let’s celebrate the power of biotechnology! Share to spread awareness.

03/12/2024

🌟 Breaking News in Biotech! 🌟

Melbourne-based biotech NEXSEN, backed by RMIT University, is making waves as it prepares for an ASX listing in April 2025. With a $2-3M pre-IPO funding round underway, supported by investors like Alium Capital, NEXSEN is set to potentially transform diagnostic testing for Group B Streptococcus (GBS) - a bacteria that can be passed from mother to baby during childbirth.

📋 Key Updates:
✅ Pre-IPO raise managed by Alpine Capital to fund marketing, test development, and clinical trials.
✅ Trials with Northern Health are set to begin after the IPO.
✅ Designed for doctors, health agencies, and home users, the rapid diagnostic tool aims to make GBS testing faster, more accessible, and more affordable worldwide.

The future of healthcare is here, and NEXSEN is leading the charge. Stay tuned for more updates! 🚀

The biotech, which has been working towards commercial development of its IP since March 2022, is targeting ASX quotation in April next year.

07/11/2024

📊 **IVD Market Set for Major Growth!**

The In Vitro Diagnostics (IVD) market is expected to grow from $85.2 billion in 2024 to $119.4 billion by 2029, with a steady annual growth rate of 6.9%. This growth is fueled by increased awareness of early disease diagnosis, rapid point-of-care (PoC) technologies, and automation. The introduction of disease-specific biomarkers and tests, as well as opportunities in emerging markets, are also contributing to this boom.

At the forefront of this progress is NEXSEN, who are working on a Group B Strep (GBS) test, with the aim to help deliver better health outcomes by enabling early diagnosis.